(19)
(11) EP 4 823 683 A1

(12)

(43) Date of publication:
21.10.2026 Bulletin 2026/43

(21) Application number: 24828351.7

(22) Date of filing: 11.12.2024
(51) International Patent Classification (IPC): 
A61P 35/00(2006.01)
C07D 513/14(2006.01)
C07D 471/14(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 513/14; C07D 471/14; A61P 35/00
(86) International application number:
PCT/EP2024/085630
(87) International publication number:
WO 2025/125302 (19.06.2025 Gazette 2025/25)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 11.12.2023 GB 202318867

(71) Applicant: Genome Therapeutics Ltd
London SE19 3HF (GB)

(72) Inventor:
  • MEO, Paul
    Cambridge Lensfield Road Cambridge CB2 1EW (GB)

(74) Representative: Johnson, Stephen William et al
Venner Shipley LLP 406 Cambridge Science Park Milton Road
Cambridge CB4 0WW
Cambridge CB4 0WW (GB)

   


(54) NOVEL COMPOUNDS